中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
Engineered nanotechnology for epigenetic therapy in cancer treatment

文献类型：期刊论文

作者Li, Yan2; Li, Yang4,5; Tan, Yuan2; Cai, Yanan3; Liu, Xinfeng6; Wei, Chao6; Yu, Wenjun6; Fu, Yuanlei2; Cao, Haiqiang1,2,6
刊名CHEMICAL ENGINEERING JOURNAL
出版日期2025-12-01
卷号525页码:23
关键词Clinical translation Epigenetic regulation Cancer treatment Epigenetic nanomedicine Targeted delivery Stimuli responsive
ISSN号1385-8947
DOI10.1016/j.cej.2025.170485
通讯作者Yu, Wenjun(wjyu@baridd.ac.cn) ; Fu, Yuanlei(ylfu@yimm.ac.cn) ; Cao, Haiqiang(caohaiqiang1@simm.ac.cn)
英文摘要The reversible and dynamic nature of epigenetic regulation, which occurs without permanent DNA sequence changes, plays a crucial role in the pathogenesis of cancer. To date, at least twelve epigenetic drugs have been approved by the FDA for cancer treatment. However, the majority of these agents are developed for hematological malignancies, with only three epigenetic agents approved for the treatment of solid tumors. Besides, a limited number of epigenetic drugs can effectively reach the tumor site in vivo. This is partly due to off-target effects and various delivery barriers, including pharmacokinetic variability and immune clearance. Additionally, the unsatisfactory release profiles of epigenetic drugs negatively affect the treatment efficacy. To address these limitations, engineered nanocarriers, such as polymeric nanoparticles, offer a promising strategy. They provide several advantages over conventional pharmaceuticals, including enhanced targeting and pharmacokinetic control, increased retention at the tumor site, and responsive drug release. This review summarizes the mechanisms of epigenetics, including DNA methylation, histone modification, and non-coding RNA. Furthermore, we introduce the application of engineered nanotechnology, along with the advantages and disadvantages of each platform used for delivering epigenetic drugs in cancer treatment. The primary objective is the construction of delivery vehicles from a materials science perspective, focusing on the mechanisms that facilitate targeted delivery and controlled release of epigenetic drugs. We also conducted a discussion on the challenges involved in the clinical translation of epigenetic nanoparticles for cancer treatment.
WOS关键词DRUG-DELIVERY SYSTEMS ; OVERCOMING BIOLOGICAL BARRIERS ; GOLD NANORODS ; CO-DELIVERY ; NANOPARTICLES ; NANOCARRIERS ; STRATEGIES ; THERAPEUTICS ; MECHANISMS ; INHIBITION
资助项目National Natural Science Foundation of China[32070927] ; Natural Science Foundation of Shandong Province[ZR2023MC121] ; Basic Research Project of Yantai Science and Technology Innovation Development Plan[2023JCYJ064]
WOS研究方向Engineering
语种英语
WOS记录号WOS:001619485000014
出版者ELSEVIER SCIENCE SA
源URL[http://119.78.100.183/handle/2S10ELR8/322067]  
专题中国科学院上海药物研究所
通讯作者Yu, Wenjun; Fu, Yuanlei; Cao, Haiqiang
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China
2.Yantai Inst Pharmaceut Sci, Yantai Key Lab Nanomed & Adv Preparat, Yantai 264000, Shandong, Peoples R China
3.Yantai Univ, Sch Pharm, Yantai 264005, Peoples R China
4.Shandong First Med Univ & Shandong Acad Med Sci, Inst Mat Med, Jinan 250117, Peoples R China
5.Shandong First Med Univ & Shandong Acad Med Sci, Sch Pharmaceut Sci, Jinan 250117, Peoples R China
6.Shandong Lab Yantai Drug Discovery, Bohai Rim Adv Res Inst Drug Discovery, Yantai 264117, Shandong, Peoples R China
推荐引用方式
GB/T 7714		 Li, Yan,Li, Yang,Tan, Yuan,et al. Engineered nanotechnology for epigenetic therapy in cancer treatment[J]. CHEMICAL ENGINEERING JOURNAL,2025,525:23.
APA Li, Yan.,Li, Yang.,Tan, Yuan.,Cai, Yanan.,Liu, Xinfeng.,...&Cao, Haiqiang.(2025).Engineered nanotechnology for epigenetic therapy in cancer treatment.CHEMICAL ENGINEERING JOURNAL,525,23.
MLA Li, Yan,et al."Engineered nanotechnology for epigenetic therapy in cancer treatment".CHEMICAL ENGINEERING JOURNAL 525(2025):23.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。